Events

Completed Events

18Jan
10th HiPEAC PARMA-DITAM 2016

Clarion Congress Hotel Prague, Czech Republic

19Jan
10th HiPEAC Workshop on Reconfigurable Computing

Clarion Congress Hotel Prague, Czech Republic

08Mar
Plenary Meeting - Milan, Italy

Milan, Italy

29May
pHealth 2016 international conference

Heraklion, Crete, Greece

09Jun
21st Annual Meeting of the European Haematology Association

Bella Center - Copenhagen, Denmark

10Nov
AEGLE at the iTECHLAW in Madrid

Madrid, Spain

15Nov
AEGLE at ISSE 2016 in Paris

Paris, France

17Nov
Big Data Spain

Madrid, Spain

28Mar
AEGLE at DATE2017 Conference

Laussane, Switzerland

24Apr
Informatics for Health 2017

Manchester, UK

10May
eHealth Week 2017

Malta

19Sep
Data revolution in Healthcare

Barcelona, Spain

04Oct
Impact of Big Data Analytics on Healthcare

Luxembourg, Luxembourg

16Nov
Big Data Spain 2017

Madrid, Spain

All events
Back to list

5th International Conference on Myelodysplastic Syndromes

14th April 2016 - 16th April 2016

Estoril, Portugal

Over the past few years, the revolution of genomic and epigenomic analysis (going as far as whole genome sequencing) has led to the discovery of most of the genes that seem to be involved in the pathogenesis of MDS. Very large patient series where gene abnormalities have been studied will be presented

Over the past few years, the revolution of genomic and epigenomic analysis (going as far as whole genome sequencing) has led to the discovery of most of the genes that seem to be involved in the pathogenesis of MDS. Very large patient series where gene abnormalities have been studied will be presented

In addition, clinicians are starting to use  those genetic and epigenetic alterations to improve diagnosis and risk stratification, and a few of these abnormalities are beginning to  constitute treatment targets

Prognostic factors of MDS have improved, especially with the publication of the revised IPSS, which allows in particular to identify « low risk MDS » patients whose outcome may in fact not be so favorable, and who may require treatment generally considered for higher risk patients. Genetic analysis is playing a growing role in this risk stratification.

Regarding treatment, a major challenge in high risk MDS is to improve results of hypomethylating agents, probably by using drug combinations, and also by making allogeneic SCT available to more patients, which has been achieved in part by the improvements in transplants with alternative donors. In low risk MDS, the precise role of TPO receptors agonists and of iron chelation, among others, will be debated, while the major challenge remains that of anemia resistant to erythropoietic stimulating agents

Learning objectives:
– Learn how to optimally diagnose MDS, mainly by morphological analysis and cytogenetics, but also using molecular analysis and flow cytometry.

- Improve ability to analyze prognostic factors, including new ones (revised IPSS, molecular analysis).
 
– Review current treatment of MDS, in both the high risk and low risk settings, ranging from single follow up to allogeneic stem cell  transplantation.
 
– Acquire improved knowledge of emerging treatments, based on targeted therapies and well conducted clinical trials.

- Diagnostic, prognostic and therapeutic issues will be largely discussed based on clinical cases that will be presented by the faculty and by selected delegates.

More details at:

Interest Form

Captcha
Required*